Dyadic International, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 12, 2021 at 04:07 pm EDT
Share
Dyadic International, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 3.867 million compared to USD 2.798 million a year ago. Net loss was USD 3.846 million compared to USD 2.651 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.1 a year ago. For the half year, operating loss was USD 7.187 million compared to USD 5.180 million a year ago. Net loss was USD 7.141 million compared to USD 4.865 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.18 a year ago.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
